Quest for the right Drug
פרבנאר 20 PREVENAR 20 (PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 14, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 18C, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19 F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8, PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V)
צורת מתן:
תוך-שרירי : I.M
צורת מינון:
תרחיף להזרקה : SUSPENSION FOR INJECTION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects Summary of the safety profile Participants 18 years of age and older The safety of Prevenar 20 was evaluated in 4,552 participants 18 years of age and older in six clinical trials (two Phase 1, one Phase 2, and three Phase 3), and 2,496 participants in the control groups. In the Phase 3 trials, 4,263 participants received Prevenar 20. This, included 1,798 participants 18 through 49 years of age, 334 participants 50 through 59 years of age, and 2,131 participants 60 years of age and older (1,138 were 65 years of age and older). Of the participants who received Prevenar 20 in the Phase 3 trials, 3,639 were naïve to pneumococcal vaccines, 253 had previously received Pneumovax 23 (pneumococcal polysaccharide vaccine [23-valent]; PPSV23) (≥ 1 to ≤ 5 years prior to enrollment), 246 had previously received Prevenar 13 only (≥ 6 months prior to enrollment), and 125 had previously received Prevenar 13 followed by PPSV23 (the dose of PPSV23 ≥ 1-year prior to enrollment). Participants in the Phase 3 trial B7471007 (Pivotal Study 1007) were evaluated for adverse events for 1 month after vaccination, and serious adverse events through 6 months after vaccination. This study included 447 participants 18 to 49 years of age, 445 participants 50 to 59 years of age, 1,985 participants 60 to 64 years of age, 624 participants 65 to 69 years of age, 319 participants 70 to 79 years of age, and 69 participants ≥ 80 years of age. In participants 18 to 49 years of age in Studies 1007 and a Phase 3 trial B7471008 (Lot Consistency Study 1008), the most frequently reported adverse reactions were pain at injection site (79.2%), muscle pain (62.9%), fatigue (46.7%), headache (36.7%), and joint pain (16.2%). In participants 50 to 59 years of age in Study 1007, the most frequently reported adverse reactions were pain at injection site (72.5%), muscle pain (49.8%), fatigue (39.3%), headache (32.3%), and joint pain (15.4%). In participants ≥ 60 years of age in Study 1007, the most frequently reported adverse reactions were pain at injection site (55.4%), muscle pain (39.1%), fatigue (30.2%), headache (21.5%), and joint pain (12.6%). These were usually mild or moderate in intensity and resolved within a few days after vaccination. Phase 3 Study B7471006 (Study 1006) evaluated Prevenar 20 in participants ≥ 65 years of age with varying prior pneumococcal status (prior PPSV23, prior Prevenar 13 or prior Prevenar 13 followed by PPSV23). In this study, the most frequently reported adverse reactions for participants were similar in frequency to those described for participants ≥ 60 years of age in Study 1007, with slightly higher injection site pain (61.2%) in participants with prior Prevenar 13, and joint pain (16.8%) in participants with prior Prevenar 13 followed by PPSV23. Tabulated list of adverse reactions Tabulated lists of adverse reactions from the Phase 3 clinical trials and postmarketing experience are presented below. 2023-0084870 Adverse reactions from clinical trials As Prevenar 20 contains the same 13 serotype-specific capsular polysaccharide conjugates and the same vaccine excipients as Prevenar 13, the adverse reactions already identified for Prevenar 13 have been adopted for Prevenar 20. Table 1 presents adverse reactions reported in Phase 3 trials of Prevenar 20, based on the highest frequency among adverse reactions, local reactions, or systemic events after vaccination in any Prevenar 20 group. In clinical trials, the safety profile of Prevenar 20 was similar to that of Prevenar 13. No new adverse reactions were identified as compared to Prevenar 13. Adverse reactions are listed by system organ class in decreasing order of frequency and seriousness. The frequency is defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from available data). Table 1. Adverse Drug Reactions From Prevenar 20 Clinical Trials System Organ Class Very Common Common Uncommon Frequency Not Known Immune system Hypersensitivity disorders reaction, including face oedema, dyspnoea, bronchospasm Metabolism and Decreased nutrition disorders appetitea Nervous system Headache disorders Gastrointestinal Diarrhoeaa disorders Nausea Vomitinga Skin and Rasha subcutaneous tissue Angioedema disorders Musculoskeletal and Joint pain connective tissue Muscle pain disorders General disorders Vaccination-site Vaccination-site Vaccination-site Limitation of and administration pain/tenderness induration/swellinga pruritus arm site conditions Fatigue Vaccination-site Lymphadenopathy movementa erythemaa Vaccination-site Pyrexia urticaria Chillsa a. Event reported in clinical trials with Prevenar 13 with very common frequency (≥ 1/10). Decreased appetite and limitation of arm movement were not reported in the adult Phase 3 trials of Prevenar 20; therefore, the frequency is not known. Safety with concomitant vaccine administration in adults When Prevenar 20 was administered to adults aged ≥ 65 years together with the third (booster) dose of a COVID-19 mRNA vaccine (nucleoside modified), the tolerability profile generally resembled that of the COVID-19 mRNA vaccine (nucleoside modified) administered alone. There were a few differences in the safety profile when compared to administration of Prevenar 20 alone. In the phase 3 trial B7471026 (Study 1026), pyrexia (13.0%) and chills (26.5%) were reported as “very common” with co-administration. There was also one report of dizziness (0.5%) in the co-administration group. 2023-0084870 Adverse reactions from postmarketing experience Table 2 includes adverse experiences that have been spontaneously reported during the postmarketing use of Prevenar 13, which may also occur with Prevenar 20. The postmarketing safety experience with Prevenar 13 is relevant to Prevenar 20, as Prevenar 20 contains all components (polysaccharide conjugates and excipients) of Prevenar 13. These events were reported voluntarily from a population of uncertain size. Therefore, it is not possible to reliably estimate their frequency or to establish, for all events, a causal relationship to vaccine exposure. Table 2. Adverse Reactions From Prevenar 13 Postmarketing Experience System Organ Class Frequency Not Known Immune system disorders Anaphylactic/anaphylactoid reaction, including shock Skin and subcutaneous tissue disorders Erythema multiforme General disorders and administration site Vaccination-site dermatitis conditions Events reported spontaneously in Prevenar 13 postmarketing experience; therefore, the frequencies could not be estimated from the available data and are considered as not known. Additional information in special populations in studies with Prevenar 13 Participants ≥ 18 years of age with HIV infection have similar frequencies of adverse reactions in Table 1, except for pyrexia (5% to 18%) and vomiting (8% to 12%) which were very common and nausea (< 1% to 3%) which was common. Participants ≥ 18 years of age with an HSCT have similar frequencies of adverse reactions in Table 1, except for pyrexia (4% to 15%), vomiting (6% to 21%), and diarrhoea (25% to 36%) which were very common. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form https://sideeffects.health.gov.il/
פרטי מסגרת הכללה בסל
התכשיר יינתן לחיסון כנגד סטרפטוקוקוס פנאומוניה במבוגרים בני 65 שנים ומעלה אשר לא עונים על הגדרות קבוצת סיכון גבוה במיוחד למחלה פנאומוקוקלית בתדריך החיסונים של משרד הבריאות.
מסגרת הכללה בסל
התוויות הכלולות במסגרת הסל
התוויה | תאריך הכללה | תחום קליני | Class Effect | מצב מחלה |
---|---|---|---|---|
התכשיר יינתן לחיסון כנגד סטרפטוקוקוס פנאומוניה במבוגרים בני 65 שנים ומעלה אשר לא עונים על הגדרות קבוצת סיכון גבוה במיוחד למחלה פנאומוקוקלית בתדריך החיסונים של משרד הבריאות. | 01/02/2023 | מחלות זיהומיות | סטרפטוקוקוס פנאומוניה |
מידע נוסף